Adisseo(SH:600299)2016-10-28 16:00Financial Performance - Operating revenue decreased by 34% to CNY 8.09 billion from CNY 12.23 billion in the same period last year[7] - Net profit attributable to shareholders increased by 26% to CNY 1.55 billion from CNY 1.23 billion year-on-year[7] - The company expects net profit for the full year 2016 to exceed budget targets despite market competition[9] - Vitamin A prices increased by 100% compared to the same period last year, contributing to profitability[9] - The company experienced a decrease in net income, with a reported loss of -657,917 for the quarter[12] - Net profit for Q3 2016 was ¥551,177,294, a decline of 34.3% from ¥840,511,635 in Q3 2015[38] - Net profit attributable to the parent company for Q3 2016 was CNY 530,976,866, compared to CNY 967,684,458 in the same period last year, representing a decline of approximately 45%[39] Assets and Liabilities - Total assets increased by 13% to CNY 20.32 billion compared to CNY 17.91 billion at the end of the previous year[7] - The company's total equity reached CNY 15.86 billion, up from CNY 14.18 billion, marking an increase of around 11.8%[30] - The total current liabilities rose to CNY 2.70 billion from CNY 2.18 billion, indicating an increase of approximately 23.6%[30] - The company's non-current liabilities totaled CNY 1.76 billion, up from CNY 1.55 billion, reflecting an increase of approximately 13.5%[30] - Total liabilities decreased to ¥27,420,889 in Q3 2016 from ¥67,895,192 in Q3 2015, a reduction of 59.6%[34] Cash Flow - The company’s cash flow from investment activities showed a net outflow of RMB 376,806,293, a decrease of 49% compared to RMB 741,877,068 in the previous year[21] - Net cash flow from operating activities for the first nine months of 2016 was CNY 2,177,559,777, down from CNY 2,996,137,456 in the previous year[43] - Cash and cash equivalents at the end of Q3 2016 totaled CNY 6,216,474,931, an increase from CNY 3,246,868,337 at the end of Q3 2015[44] - Investment activities resulted in a net cash outflow of CNY 376,806,293 for the first nine months of 2016, compared to a net outflow of CNY 741,877,068 in the same period last year[44] - Financing activities generated a net cash outflow of CNY 701,821,947 in the first nine months of 2016, compared to a net outflow of CNY 624,186,419 in the previous year[44] Shareholder Information - The total number of shareholders reached 24,148 by the end of the reporting period[13] - China BlueStar (Group) Co., Ltd. holds 2,389,387,160 shares, accounting for 89.09% of the total shares[13] - The top ten shareholders include various funds and individuals, with the largest being China BlueStar[13] Cost Management - The company has implemented stricter cost control measures to maintain high profit levels despite declining prices[9] - The operating cost for the same period was RMB 4,060,835,069, down 45% from RMB 7,394,371,277, also affected by the asset restructuring[19] Research and Development - The company continues to invest in research and development to ensure cutting-edge technology in methionine production[9] Other Financial Metrics - The effective tax rate for the period was 32%, with a tax impact amounting to 1,854,619[12] - The company reported a total loss of -3,277,043, with a significant portion attributed to miscellaneous expenses[12] - Major asset restructuring during the reporting period led to significant changes in key financial metrics[15] - The report indicates a notable change in financial indicators due to the completion of major asset restructuring[15]